RECORD // Company

Annovis Bio, Inc.

Formerly: QR Pharma, Inc.

Built 2026-11-22T00:40:02Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
  • ANNOVIS BIO, INC. · legal entity in this company's GLEIF ownership tree (LEI 549300IFBVI51FN3NJ32)
SEC EDGAR (1)
Matched by name only, not merged (1)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Annovis Bio Inc. · Ctgov · same registered legal name as 'Annovis Bio, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

3 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-13 · accession 0001104659-26-127105

ItemValuePeriodFormFiledAccessionReport
Revenue$09 months ended 2026-09-3010-Q2026-11-130001104659-26-1271052026-11-22 00:40 UTCReport an error
Net income (loss)$-9,462,1363 months ended 2026-09-3010-Q2026-11-130001104659-26-1271052026-11-22 00:40 UTCReport an error
Cash and cash equivalents$2,819,898at 2026-09-3010-Q2026-11-130001104659-26-1271052026-11-22 00:40 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001477845
Ticker
ANVS
EIN
262540421
UEI
LS3NJ5K64FH8
CUSIP
03615A108
Record ID
sx:sec:0001477845

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

37 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-13SEC EDGAR company profile2026-11-22 00:40 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-13SEC EDGAR company profile2026-11-22 00:40 UTCReport an error
State of incorporationDE2026-11-13SEC EDGAR company profile2026-11-22 00:40 UTCReport an error
Fiscal year end (MMDD)12312026-11-13SEC EDGAR company profile2026-11-22 00:40 UTCReport an error
Business address101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA, 193552026-11-13SEC EDGAR company profile2026-11-22 00:40 UTCReport an error
ExchangesNYSE2026-11-13SEC EDGAR company profile2026-11-22 00:40 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$02025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-22 00:40 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-28,854,1972025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:40 UTCReport an error
Total assets (at 2025-12-31)$21,081,6252025-12-3110-K, XBRL Assets2026-11-22 00:40 UTCReport an error
Stockholders' equity (at 2025-12-31)$16,851,2502025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:40 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$19,532,3382025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:40 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-25,619,7032025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:40 UTCReport an error
Form D total offering amount (D filed 2023-04-25)$1,064,9522023-04-25D2026-11-22 00:40 UTCReport an error
Form D total amount sold (D filed 2023-04-25)$1,064,9522023-04-25D2026-11-22 00:40 UTCReport an error
Form D industry groupBiotechnology2023-04-25D2026-11-22 00:40 UTCReport an error
Form D revenue rangeDecline to Disclose2023-04-25D2026-11-22 00:40 UTCReport an error
Form D date of first sale2023-04-072023-04-25D2026-11-22 00:40 UTCReport an error
8-K Item 2.02 (filed 2026-11-13)Results of Operations and Financial Condition. On November 13, 2026, Annovis Bio, Inc. (the “Registrant”) issued a press release reporting earnings for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99 hereto and incorporated herein by reference.2026-11-13SEC EDGAR 8-K 0001104659-26-127094 (text as filed, excerpt)2026-11-22 00:40 UTCReport an error
8-K Item 1.01 (filed 2026-11-05)Entry into a Material Definitive Agreement. On November 5, 2026, Annovis Bio, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”), dated as of November 5, 2026, with Canaccord Genuity LLC, as underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell, in a public offering (the “Offering”) (i) an aggregate of 19,000,000 shares of common stock (the “Shares”), $0.0001 par value per share (the “Common Stock”), of the Company and, in lieu of Common Stock to certain investors, pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 2,000,000 shares of Common Stock, and (ii) accompanying warrants to purchase up to…2026-11-05SEC EDGAR 8-K 0001104659-26-123467 (text as filed, excerpt)2026-11-22 00:40 UTCReport an error
8-K Item 7.01 (filed 2026-11-05)Regulation FD Disclosure On November 4, 2026, the Company issued a press release announcing the launch of the Offering. On November 5, 2026, the Company issued a press release announcing the pricing of the Offering. Copies of the press releases are furnished as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated by reference herein. The information contained in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a…2026-11-05SEC EDGAR 8-K 0001104659-26-123467 (text as filed, excerpt)2026-11-22 00:40 UTCReport an error
8-K Item 2.02, Results of Operations and Financial (filed 2026-11-04)Condition. Annovis Bio, Inc. (the “Company”) is providing the following information about its preliminary cash and cash equivalents as of September 30, 2026. Based on preliminary estimates and currently available information, the Company estimates that its cash and cash equivalents were approximately $2.8 million as of September 30, 2026. The Company’s interim financial statements as of and for the three and nine months ended September 30, 2026 are not yet available and the Company has not yet completed its quarterly financial closing processes for the period ended September 30, 2026. As such, the foregoing information reflects the Company’s estimates with respect to cash and cash…2026-11-04SEC EDGAR 8-K 0001104659-26-122665 (text as filed, excerpt)2026-11-22 00:40 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-04)The disclosure set forth above under Item 2.02 of this Current Report on Form 8-K is incorporated by reference into this Item 7.01. The information contained in Item 2.02 and Item 7.01 of this Current Report on Form 8-K is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such a filing.2026-11-04SEC EDGAR 8-K 0001104659-26-122665 (text as filed, excerpt)2026-11-22 00:40 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-04)The disclosure set forth above under Item 2.02 of this Current Report on Form 8-K is incorporated by reference into this Item 8.01.2026-11-04SEC EDGAR 8-K 0001104659-26-122665 (text as filed, excerpt)2026-11-22 00:40 UTCReport an error
8-K Item 5.03 (filed 2026-11-04)Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year On November 3, 2026, Annovis Bio, Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”) telephonically. At the Special Meeting, among other things, the stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 70,000,000 to 140,000,000 (the “Charter Amendment”). The Company filed the Charter Amendment with the Secretary of State of the State of Delaware on November 4, 2026. The foregoing description is only a summary and is qualified in its entirety by reference to…2026-11-04SEC EDGAR 8-K 0001104659-26-122656 (text as filed, excerpt)2026-11-22 00:40 UTCReport an error
8-K Item 5.07, Submission of Matters to a Vote of Security Holders (filed 2026-11-04)At the Special Meeting, two proposals were submitted to the Company’s stockholders and all matters voted upon were approved with the required votes. The proposals are outlined below and further described in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission (the “SEC’) on September 11, 2026, and the supplement thereto filed with the SEC on October 7, 2026. At the Special Meeting, a total of 28,301,063 shares of the Company’s common stock, or 66.31% of the common stock outstanding as of September 4, 2026, the record date for the Special Meeting, were represented virtually or by proxy. The following is a brief description of the final voting…2026-11-04SEC EDGAR 8-K 0001104659-26-122656 (text as filed, excerpt)2026-11-22 00:40 UTCReport an error
Largest institutional holder #1 (13F as filed): Empery Asset Management, LP$4,466,7452026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:40 UTCReport an error
Largest institutional holder #2 (13F as filed): MARSHALL WACE, LLP$3,426,7502026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:40 UTCReport an error
Largest institutional holder #3 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$3,064,0192026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:40 UTCReport an error
Largest institutional holder #4 (13F as filed): TUDOR INVESTMENT CORP ET AL$2,524,2692026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:40 UTCReport an error
Largest institutional holder #5 (13F as filed): RENAISSANCE TECHNOLOGIES LLC$1,864,0922026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:40 UTCReport an error
Largest institutional holder #6 (13F as filed): TWO SIGMA INVESTMENTS, LP$1,078,0022026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:40 UTCReport an error
Largest institutional holder #7 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$528,1342026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:40 UTCReport an error
Largest institutional holder #8 (13F as filed): BlackRock, Inc.$464,7322026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:40 UTCReport an error
Largest institutional holder #9 (13F as filed): CITADEL ADVISORS LLC$453,2492026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:40 UTCReport an error
Largest institutional holder #10 (13F as filed): VANGUARD FIDUCIARY TRUST CO$330,2062026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:40 UTCReport an error
Federal award transactions, fiscal year 2026 (this one registration only)$02026-09-30USAspending recipient profile2026-11-22 00:40 UTCReport an error
Number of federal award transactions, fiscal year 2026 (this one registration only)02026-09-30USAspending recipient profile2026-11-22 00:40 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.